Armata Pharmaceuticals creates pathogen‑specific bacteriophage therapeutics to treat antibiotic‑resistant infections, using a platform that isolates natural phages and engineers them for potency, stability, and high‑purity manufacturing. Their clinical‑stage programs target WHO‑priority pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, offering targeted therapy that preserves the human microbiome.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Antibiotic overuse has driven the emergence of multidrug‑resistant bacteria, creating a growing threat of infections that are difficult or impossible to treat with existing drugs. Broad‑spectrum antibiotics also disrupt the human microbiome, leading to additional health complications.
Solution
Armata Pharmaceuticals develops pathogen‑specific bacteriophage therapeutics that target antibiotic‑resistant and hard‑to‑treat bacterial infections. By isolating natural phages and applying synthetic biology to engineer them, the company creates precise, high‑purity phage cocktails for both acute and chronic indications. Its integrated platform spans discovery, host‑cell engineering, formulation, and cGMP manufacturing, enabling rapid progression from bench to clinic. Clinical‑stage programs focus on WHO‑listed priority pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus, with Phase 2 data supporting safety and efficacy and a planned Phase 3 trial for S. aureus bacteremia. The approach offers an alternative to traditional antibiotics while preserving microbiome balance.
Target Audience
Primary customers are healthcare providers and hospital systems treating patients with multidrug‑resistant bacterial infections, as well as pharmaceutical partners seeking phage‑based therapeutic candidates for high‑unmet‑need indications.
Features
- Isolation of natural bacteriophages combined with synthetic‑biology engineering to enhance potency, stability, and manufacturability
- In‑house host‑cell adaptation platform that improves phage production yields and product purity
- Tailored formulation development for specific infection sites (e.g., respiratory, systemic, prosthetic joint)
- Fully cGMP‑compliant manufacturing suites and Quality Unit for clinical‑grade material production
- Comprehensive preclinical and clinical pipeline covering cystic fibrosis, non‑CF bronchiectasis, pneumonia, bacteremia, and prosthetic joint infection
- Proprietary analytics and surveillance system for long‑term phage product lifecycle management